.

Deeper Knowledge, Faster

  • Plan your formulary budget
  • Predict branded drug patent expiration
  • Uncover prior art in expired and abandoned patents

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Cantor Fitzgerald
Queensland Health
Covington
Accenture
US Department of Justice
Chinese Patent Office
Express Scripts
Fuji
Healthtrust
Harvard Business School

Generated: July 21, 2017

DrugPatentWatch Database Preview

AKTEN Drug Profile

« Back to Dashboard

What is the patent landscape for Akten, and when can generic versions of Akten launch?

Akten is a drug marketed by Akorn and is included in one NDA. There is one patent protecting this drug.

This drug has two patent family members in two countries.

The generic ingredient in AKTEN is lidocaine hydrochloride. There are twenty-nine drug master file entries for this compound. Forty-six suppliers are listed for this compound. Additional details are available on the lidocaine hydrochloride profile page.

Summary for Tradename: AKTEN

Patents:1
Applicants:1
NDAs:1
Suppliers / Packagers: see list1
Bulk Api Vendors: see list90
Clinical Trials: see list4
Patent Applications: see list6
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:AKTEN at DailyMed

Pharmacology for Tradename: AKTEN

Ingredient-typeAmides
Drug ClassAmide Local Anesthetic
Antiarrhythmic
Physiological EffectLocal Anesthesia
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Akorn
AKTEN
lidocaine hydrochloride
GEL;OPHTHALMIC022221-001Oct 7, 2008RXYesYes8,759,401► SubscribeY ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: AKTEN

Country Document Number Estimated Expiration
World Intellectual Property Organization (WIPO)2008014036► Subscribe
European Patent Office2043601► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Express Scripts
Chubb
Fish and Richardson
Baxter
Medtronic
Cantor Fitzgerald
Dow
Cipla
Covington
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot